

# Lynne T Haber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/183879/publications.pdf>

Version: 2024-02-01

46  
papers

1,490  
citations

361045

20  
h-index

329751

37  
g-index

51  
all docs

51  
docs citations

51  
times ranked

1979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of updated BMD modeling methods on perchlorate and chlorate assessments of human health hazard. <i>Toxicology Letters</i> , 2021, 340, 89-100.	0.4	3
2	Bayesian hierarchical evaluation of dose-response for peanut allergy in clinical trial screening. <i>Food and Chemical Toxicology</i> , 2021, 151, 112125.	1.8	3
3	Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 7-16.	2.2	65
4	Benchmark dose (BMD) modeling: current practice, issues, and challenges. <i>Critical Reviews in Toxicology</i> , 2018, 48, 387-415.	1.9	131
5	Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 92, 1-7.	1.3	50
6	Dose and temporal evaluation of ethylene oxide-induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 122-134.	0.9	10
7	Derivation of an oral toxicity reference value for nickel. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 87, S1-S18.	1.3	31
8	Framework for human health risk assessment of non-cancer effects resulting from short-duration and intermittent exposures to chemicals. <i>Journal of Applied Toxicology</i> , 2016, 36, 1077-1089.	1.4	9
9	Mode-of-action evaluation for the effect of trans fatty acids on low-density lipoprotein cholesterol. <i>Food and Chemical Toxicology</i> , 2016, 98, 282-294.	1.8	3
10	Advancing Risk Analysis for Nanoscale Materials: Report from an International Workshop on the Role of Alternative Testing Strategies for Advancement. <i>Risk Analysis</i> , 2016, 36, 1520-1537.	1.5	16
11	Meta-regression analysis of the effect of trans fatty acids on low-density lipoprotein cholesterol. <i>Food and Chemical Toxicology</i> , 2016, 98, 295-307.	1.8	14
12	Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2015, 789-790, 53-60.	0.9	10
13	Evaluation of cll mutations in lung of male Big Blue mice exposed by inhalation to vanadium pentoxide for up to 8 weeks. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2015, 789-790, 46-52.	0.9	11
14	Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting. <i>Journal of Occupational and Environmental Hygiene</i> , 2015, 12, S41-S54.	0.4	31
15	Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 151-163.	1.3	33
16	A framework for fit-for-purpose dose response assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2013, 66, 234-240.	1.3	14
17	Application of Markov chain Monte Carlo analysis to biomathematical modeling of respirable dust in US and UK coal miners. <i>Regulatory Toxicology and Pharmacology</i> , 2013, 66, 47-58.	1.3	7
18	A four-step approach to evaluate mixtures for consistency with dose addition. <i>Toxicology</i> , 2013, 313, 134-144.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Advancing human health risk assessment: Integrating recent advisory committee recommendations. <i>Critical Reviews in Toxicology</i> , 2013, 43, 467-492.	1.9	42
20	Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide. <i>Toxicological Sciences</i> , 2013, 136, 26-38.	1.4	22
21	Impact of Chemical Proportions on the Acute Neurotoxicity of a Mixture of Seven Carbamates in Prewanling and Adult Rats. <i>Toxicological Sciences</i> , 2012, 129, 126-134.	1.4	27
22	Cholinesterase inhibition and depression of the photic after discharge of flash evoked potentials following acute or repeated exposures to a mixture of carbaryl and propoxur. <i>NeuroToxicology</i> , 2012, 33, 332-346.	1.4	7
23	Critical review of doseâ€“response options for F344 rat mammary tumors for acrylamide â€“ Additional insights based on mode of action. <i>Food and Chemical Toxicology</i> , 2012, 50, 1763-1775.	1.8	18
24	Linear low-dose extrapolation for noncancer health effects is the exception, not the rule. <i>Critical Reviews in Toxicology</i> , 2011, 41, 1-19.	1.9	108
25	A Bayesian Network Model for Biomarker-Based Dose Response. <i>Risk Analysis</i> , 2010, 30, 1037-1051.	1.5	29
26	Evaluation of concentrationâ€“response options for diacetyl in support of occupational risk assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 285-296.	1.3	24
27	Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. <i>Regulatory Toxicology and Pharmacology</i> , 2009, 53, 134-149.	1.3	16
28	Analysis of in vivo mutation data can inform cancer risk assessment. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, 151-161.	1.3	26
29	Evidence-based doseâ€“response assessment for thyroid tumorigenesis from acrylamide. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 52, 264-289.	1.3	36
30	Copper and Human Health: Biochemistry, Genetics, and Strategies for Modeling Dose-response Relationships. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2007, 10, 157-222.	2.9	276
31	Data considerations for regulation of water contaminants. <i>Toxicology</i> , 2006, 221, 217-224.	2.0	17
32	Using Best Science in Cancer Risk Assessment. <i>Human and Ecological Risk Assessment (HERA)</i> , 2006, 12, 1-8.	1.7	4
33	Views on Key Issues Facing the Chemical Industry. , 2005, , 27-88.		0
34	Assessing Biomarker use in Risk Assessmentâ€“A Survey of Practitioners. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2004, 67, 687-695.	1.1	12
35	Incorporation of Pharmacokinetic and Pharmacodynamic Data into Risk Assessments. <i>Toxicology Mechanisms and Methods</i> , 2004, 14, 145-158.	1.3	15
36	Confirmation of an acute no-observed-adverse-effect and low-observed-adverse-effect level for copper in bottled drinking water in a multi-site international study. <i>Regulatory Toxicology and Pharmacology</i> , 2003, 38, 389-399.	1.3	39

#	ARTICLE	IF	CITATIONS
37	An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion. <i>Toxicological Sciences</i> , 2002, 70, 120-139.	1.4	51
38	Improving Risk Assessment: Toxicological Research Needs. <i>Human and Ecological Risk Assessment (HERA)</i> , 2002, 8, 1405-1419.	1.7	3
39	Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment. <i>Human and Ecological Risk Assessment (HERA)</i> , 2002, 8, 1421-1444.	1.7	7
40	Genetic Polymorphisms in Assessing Interindividual Variability in Delivered Dose. <i>Regulatory Toxicology and Pharmacology</i> , 2002, 35, 177-197.	1.3	55
41	Scientific Criteria Used for the Development of Occupational Exposure Limits for Metals and Other Mining-Related Chemicals. <i>Regulatory Toxicology and Pharmacology</i> , 2002, 36, 262-279.	1.3	25
42	Hazard Identification and Dose Response of Inhaled Nickel-Soluble Salts. <i>Regulatory Toxicology and Pharmacology</i> , 2000, 31, 210-230.	1.3	102
43	Hazard Identification and Dose Response of Ingested Nickel-Soluble Salts. <i>Regulatory Toxicology and Pharmacology</i> , 2000, 31, 231-241.	1.3	23
44	Non-Cancer Risk Assessment for Nickel Compounds: Issues Associated with Dose-Response Modeling of Inhalation and Oral Exposures. <i>Toxicological Sciences</i> , 1998, 43, 213-229.	1.4	5
45	Non-Cancer Risk Assessment for Nickel Compounds: Issues Associated with Dose-Response Modeling of Inhalation and Oral Exposures. <i>Toxicological Sciences</i> , 1998, 43, 213-229.	1.4	22
46	Quantitative Modeling in Noncancer Risk Assessment. , 0, , 371-398.		3